Biosimilars Council June re-cap

The US Association for Accessible Medicines’ (AAM) Biosimilars Council has released an update on major developments in the biosimilars sector by executive director Craig Burten.

In the month of June, both chambers of Congress made progress in advancing legislation to  reauthorize the Biosimilar User Fee Act (BsUFA), with the House of Representatives passing its bill, and the Senate HELP Committee approving its version for the full Senate’s consideration.

This legislation is critical to the  future of patient access to biosimilars and provides the US Food and Drug Administration (FDA) with the resources it needs to review new biosimilar products.